The U.S. Food and Drug Administration or FDA approved Reyvow (lasmiditan) tablets of Eli Lilly and Co. as an oral medication for the acute treatment of migraine, with or without aura, in adults. However, Reyvow is not indicated for prevention of migraine. Reyvow is a new oral treatment that binds to 5-HT1F receptors with high affinity.
from RTT - Biotech https://ift.tt/32gkrxz
via IFTTT
No comments:
Post a Comment